Global Life Science Instrumentation and Research Tools Market to Reach 82.57 Billion by 2023
Genomics research is taking the center stage and replacing older methods, especially in drug discovery
Santa Clara, Calif. - November 5, 2018 (Investorideas.com Newswire) The emergence of closed loop automation systems, digital workflow management practices and IVD regulatory compliance protocols are driving the industry towards a new paradigm of connected labs. Frost & Sullivan forecasts the global life science instrumentation and research tools market to hit $82.57 billion by 2023 due to the increased spending by biopharmaceutical customers as they seek higher efficiencies throughout the clinical development lifecycle. Genomics research is taking the center stage and replacing older methods, especially in drug discovery. This segment has now overtaken proteomics arena and is likely to exhibit a faster growth rate over the next five years.
Global Life Science Instrumentation and Research Tools Market - Forecast to 2023, evaluates and discusses market projections, key trends, competitors, growth opportunities for existing companies, new entrants, and impact of digital transformation. The research scope includes instruments, equipment, reagents, chemicals, consumables, suppliers and IT solutions used research labs.
For further information on this analysis, please visit: http://frost.ly/2vr.
"The industry has witnessed a number of mergers and acquisitions (M&As) over the last 10 years as large companies were looking to aggressively expand their product portfolio and customer base and we expect that trend to continue," noted Nitin Naik, Life Sciences Global Vice President at Frost & Sullivan. "It is imperative that established players refocus to capture customer lifecycle value rather than just instrument or product sales. Furthermore, players reframing business model to implement turnkey digital workflow solutions will emerge as market leaders in the long term."
Further new growth opportunity trends include:
- Analytics based-solutions: While integration as a theme has been in existence in the industry for a long time now, applications of laboratory information management system and electronic laboratory notebook (LIMS/ELN) systems will move over tipping point during the forecast period.
- CRISPR based solutions: This platform which has broad applicability (both in vivo and ex vivo) holds immense potential to leverage machine learning based tools to automate sgRNA identification from databases and integrate results with LIMS/ELN.
Global Life Science Instrumentation and Research Tools Market - Forecast to 2023 is the latest addition to Frost & Sullivan's global Transformational Health's research and analyses, available through the Frost & Sullivan Leadership Council, which helps organizations identify a continuous flow of growth opportunities to succeed in an unpredictable future.
About Frost & Sullivan
For over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.
Global Life Science Instrumentation and Research Tools Market - Forecast to 2023
P: +1 (210) 348.1012
This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release on the Investorideas.com newswire https://www.investorideas.com/News-Upload/
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: https://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.